Last updated: May 25, 2026
Raloxifene hydrochloride supply typically breaks into two categories: active pharmaceutical ingredient (API) manufacturers and downstream pharmaceutical supply partners (intermediates, analytical testing, formulation development, and contract manufacturing for finished dosage forms). In parallel, competitor supply risk is driven by patent status (including generics and any noninfringing variants), regulatory approvals, and API manufacturing redundancies.
This page compiles the practical supplier landscape for raloxifene hydrochloride based on publicly visible manufacturer and supply-chain patterns used in generic and branded supply. It focuses on procurement-relevant decision points: API availability, finished-dose sourcing, and IP and regulatory friction that can constrain entry.
Who supplies raloxifene hydrochloride API (active pharmaceutical ingredient)?
Typical supplier archetypes
- Direct API manufacturers supplying raloxifene hydrochloride API to generic drug makers and contract packagers.
- API intermediates suppliers providing key chemical building blocks used in raloxifene hydrochloride synthesis.
- CDMO/CMO networks supporting salt formation, polishing, particle size control, and scale-up for oral solids.
Procurement note that affects supplier choice
Raloxifene hydrochloride is a small-molecule oral therapy with established generic supply chains. Supplier availability is usually broad, but the key commercial bottleneck is often not “who can make it,” it is:
- whether the supplier can provide consistent particle size distribution, polymorph/purity profile, and documentation aligned with ANDA submissions and batch release expectations; and
- whether the supplier has stable regulatory standing in the jurisdictions where downstream product is marketed.
Which companies manufacture raloxifene hydrochloride (API) for generic supply?
Featured-supplier selection criteria used by buyers
- Regulatory documentation readiness: DMF/CEP access, CoA templates, impurity panels, and stability data.
- Batch-to-batch consistency: impurity control at the low thresholds typical for HPLC/SFC methods.
- Supply continuity: capacity commitment, lead-time reliability, and dual-source availability.
- Salt formation expertise: ability to deliver robust specifications for the hydrochloride salt rather than free base equivalents.
- Analytical capability: method validation, traceability, and reference standard control.
Supplier landscape reality
Raloxifene hydrochloride tends to be supplied by multi-product chemical/API manufacturers that also serve other steroidal and heteroaromatic intermediates. Many listed API sources in procurement markets are intermediates-and-final-salt producers rather than single-purpose suppliers, which matters for continuity and tech transfer.
What finished-dose manufacturers supply raloxifene hydrochloride tablets (marketed product sourcing)?
Downstream finished-dose supply is commonly covered by:
- generic pharma companies selling raloxifene HCl tablets,
- authorized generic programs, and
- contract packers/CMOs producing under licensed labeling.
Why finished-dose sourcing matters
Even when API supply is available, finished-dose lead times hinge on:
- tablet excipient compatibility and impurity carry-through,
- compression behavior tied to API particle characteristics,
- QC method fit with regulatory expectations (dissolution profiles in particular).
How do patent status and exclusivity affect raloxifene hydrochloride supplier availability?
High-level effect
Patent and regulatory exclusivity primarily affect which branded products control market entry and which generic tablet presentations can legally launch and remain on shelves. For supplier procurement, it changes:
- which downstream manufacturers are active and buying API at volume;
- which marketing authorizations are active in each country; and
- whether buyers face supply volatility around contested launches or settlements.
Procurement consequence
When a market has active Paragraph IV litigation or settlement-driven launch timing, downstream demand shifts sharply. That can temporarily concentrate purchases among fewer API suppliers that are qualified to support fast launches.
What FDA status and Orange Book listing status matter for API sourcing?
For U.S. procurement, the direct supplier relevance is indirect but real:
- Downstream ANDA holders rely on qualified suppliers that support ANDA chemistry, manufacturing, and controls (CMC).
- ANDA revisions and post-approval changes can force requalification of API sources.
Actionable buyer lens
If a finished-dose maker is planning a filing or a post-approval change, procurement tends to concentrate on API vendors with pre-existing documentation or a CMC package aligned with the finished-dose regulatory dossier.
What generic entry risks exist for raloxifene hydrochloride API and tablet supply?
Generic entry friction points
- CMC comparability and dissolution specifications for tablets.
- impurity profile drift caused by upstream intermediate variability.
- salt form and moisture control during bulk handling and granulation.
Supplier risk
API makers with limited analytical method transfer capability or less robust impurity control often become bottlenecks when a downstream manufacturer tries to scale.
Which formulations and strengths change supplier requirements?
Raloxifene hydrochloride is typically used as oral solid dosage, most commonly tablets. Buyer requirements that drive supplier differentiation include:
- API particle size and flow for consistent tableting,
- moisture sensitivity during storage,
- stability under accelerated and long-term conditions,
- impurity levels tied to the exact synthetic route and intermediate purification.
Even when the active ingredient is the same, suppliers must match the API attributes that make the downstream dissolution and stability work.
Which contract manufacturing (CDMO/CMO) partners support raloxifene hydrochloride supply?
CDMO/CMO demand clusters around:
- tablet manufacturing (granulation to compression, coating if used, packaging),
- analytical QC labs for method transfer and batch release testing,
- scale-up and process development for route optimization.
In practice, buyers often select a CDMO network that can support:
- multiple ANDA-style tech transfers,
- rapid pilot batches followed by full-scale validation runs,
- and supply chain resilience via redundant sourcing of API and excipients.
Supplier due-diligence checklist for raloxifene hydrochloride
Procurement teams typically require supplier kits that include:
- Certificate of Analysis (CoA) with impurity-by-impurity breakdown
- synthetic route description sufficient to support impurity origin discussion
- analytical method package or method references (HPLC/GC/SFC as applicable)
- stability protocol and results supporting at least accelerated conditions
- polymorph/solid-state characterization information if relevant to the supplier’s control strategy
- compliance documentation aligned to buyer quality systems (GMP status, audit history)
Key bottlenecks in raloxifene hydrochloride API supply
- Impurity control at low specification limits: small changes in intermediates can change impurity distribution.
- Salt handling: hydrochloride salt stability is affected by moisture and storage conditions.
- Documentation fit: suppliers must provide CMC content that can be adopted by downstream manufacturers.
- Burst demand: generic launch timing can compress lead times, forcing temporary single-source reliance.
Key Takeaways
- Raloxifene hydrochloride supply is driven by API manufacturers plus CDMOs/CMOs for tablet manufacturing and QC release.
- Procurement should prioritize suppliers that can deliver consistent impurity profiles, salt-form robustness, and CMC-ready documentation for ANDA-aligned quality requirements.
- Patent and regulatory timelines influence downstream ordering patterns, which can cause short-term API demand concentration and supplier qualification bottlenecks.
FAQs
1) Who are the leading raloxifene hydrochloride API suppliers used by generic manufacturers?
API supply is typically served by multi-product chemical and pharmaceutical ingredient manufacturers with documented CMC packages supporting downstream ANDA use.
2) What specifications matter most when qualifying a raloxifene hydrochloride API supplier?
Impurity panel, particle size/flow, polymorph/solid-state control where applicable, and stability under defined conditions are most important for tablet performance.
3) Can raloxifene hydrochloride be sourced via contract manufacturing without direct API procurement?
Yes, many buyers source through finished-dose CMO/CDMO networks that secure API supply and manage tablet manufacturing and QC release.
4) Does raloxifene hydrochloride API supplier choice affect dissolution performance in tablets?
Yes. API particle characteristics and impurity profile influence granulation behavior and dissolution outcomes.
5) What is the biggest risk to continuity of raloxifene hydrochloride supply?
CMC requalification risk and impurity variability across upstream routes, which can force process adjustment and delay batch approvals.
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA. ANDA Approval Letters and Related Regulatory Documents for Raloxifene Hydrochloride (as listed in Orange Book). U.S. Food and Drug Administration.
